United Therapeutics Corporation · UTHR · Next earnings

United Therapeutics Corporation reports Wednesday, Nov 4, 2026

UTHR reports before market open with consensus EPS at $6.01 and revenue at $781.1M. Last quarter: United Therapeutics’ record quarter highlights Tyvaso growth and pipeline execution

Reports Before market open0 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $6.01 Calendar consensus
Consensus revenue $781.1M Calendar consensus
Report date Nov 4, 2026 Wednesday, date estimated
Session Before market open 0 days away

Where UTHR left off: FY2026 Q3

Full report

United Therapeutics’ record quarter highlights Tyvaso growth and pipeline execution

EPS surprise — Reported — vs $6.01
Revenue surprise — Reported — vs $781.1M
Stock move +0.6% Event window
Subsequent drift 0.0% Up to 20 sessions

No formal guidance was provided in the current call analysis. Prior-quarter guidance sentiment was described as maintained, so the supplied material does not establish a numerical or directional guidance change.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • The API supplier’s OAI compliance issue could affect the ralinepag regulatory or launch timeline.
  • The delayed soft-mist inhaler NDA may defer the program’s progress and potential contribution.
  • Patient switching between YUTREPIA and Tyvaso DPI remains an area of analyst concern.
  • Regulatory requirements, clinical-trial execution, and physician adoption create uncertainty across pipeline programs.

Questions analysts left open

  • Patient-switch dynamics from YUTREPIA to Tyvaso DPI.
  • Timing and data requirements for the soft-mist inhaler NDA.
  • Clinical rationale and trial design for the PH-COPD program.
  • Potential effect of the API supplier OAI on ralinepag’s regulatory schedule.
  • Development path for the triple oral pill.

Ask FN2 about UTHR next report

Transcript, numbers and history already loaded
What should I watch for in UTHR's next earnings report?How did UTHR guide last quarter, and is consensus above or below that?Give me the bull and bear case going into UTHR earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the UTHR recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent UTHR quarters

All UTHR earnings
+0.6%FY2026 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.